Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00880178 · ClinicalTrials.gov registry record

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

A clinical trial of Cardiovascular Diseases and Heart Diseases, sponsored by University of Washington.

Completed
Registry status
324
Enrollment target
20
Study locations

NCT00880178 is a study of Cardiovascular Diseases and Heart Diseases that has completed, run by University of Washington. The registered enrollment target is 324 participants, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00880178, a study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by University of Washington.

COMPLETED
Registry status
324 participants
Enrollment target
20
Study locations

Study Summary

Coronary heart disease (CHD) is a serious health concern that affects millions of people in the United States. It is usually caused by atherosclerosis-a condition that occurs when fatty material and plaque build up on the walls of the arteries that supply blood and oxygen to the heart, causing the arteries to narrow. As the arteries narrow, blood flow to the heart can slow down or stop, which can cause chest pain, shortness of breath, heart attack, or heart failure. Another component of CHD events involves inflammatory changes that result in structural breakdown of atherosclerotic plaques. Adding niacin to statin medications may be an effective way to block inflammation in the atherosclerotic plaques. This study will examine magnetic resonance imaging (MRI) images and blood samples of participants in the AIM-HIGH study who are taking niacin plus statins or statins alone to determine the effect of these medications on inflammation in atherosclerotic plaques.

Interventions

  • DRUG Simvastatin
  • DRUG Simvastatin and Extended-Release niacin

Study Locations (20)

North Carolina

  • Duke University - Durham
  • Wake Forest University, Geriatrics - Greensboro
  • Wake Forest University, Cardiology - Winston-Salem
  • Wake Forest University, Endocrinology - Winston-Salem

Minnesota

  • University of Minnesota - Minneapolis
  • HealthPartners Riverside Clinic - Minneapolis
  • Mayo Clinic - Rochester

Pennsylvania

  • Philadelphia VA Medical Center - Philadelphia
  • Pennsylvania Cardiology Associates - Philadelphia
  • Cardiology Consultants of Philadelphia - Philadelphia

Texas

  • Baylor College of Medicine - Houston
  • Kelsey Research Foundation - Houston
  • Methodist Hospital - Houston

Alabama

  • Cardiovascular Associates - Birmingham

Arizona

  • Cardiovascular Consultants - Phoenix

California

  • Long Beach VA Medical Center - Long Beach

Delaware

  • Christiana Care Health Services - Newark

Trial Details

FieldValue
Enrollment Target 324 participants
Start Date 2008-05
Est. Completion 2011-09

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT00880178

The ClinicalTrials.gov registry entry for NCT00880178 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,973-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Simvastatin is the first listed.

NCT00880178 reports 20 study locations spanning 11 distinct geographic areas - top geographies include North Carolina, Minnesota, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00880178 about?

NCT00880178 is a clinical study titled "Plaque Inflammation and Dysfunctional HDL in AIM-HIGH". Coronary heart disease (CHD) is a serious health concern that affects millions of people in the United States. It is usually caused by atherosclerosis-a condition that occurs when fatty material and plaque build up on the walls of the arteries that supply blood and oxygen to the heart, causing the a...

What is the current status of trial NCT00880178?

This trial is currently completed. The enrollment target is 324 participants. The study started on 2008-05. Estimated completion is 2011-09.

What conditions does trial NCT00880178 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Myocardial Infarction, Coronary Disease.

What interventions are being tested in trial NCT00880178?

The interventions under investigation include: Simvastatin (DRUG), Simvastatin and Extended-Release niacin (DRUG).

Who is sponsoring clinical trial NCT00880178?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00880178 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.